Back to Dashboard








AbbVie Inc. (ABBV)
Real-time intraday values
Market Overview
From:
To:
ABBV Intraday
No data available
SymbolABBV
IPO DateJan 2, 2013
CEOMr. Scott T. Reents
Full Time Employees57k
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUnited States
ExchangeNYSE
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | -0.72% | -1.91 US$ |
| 5 Days | -0.28% | -0.75 US$ |
| 1 Month | +0.12% | +0.31 US$ |
| 6 Months | +25.70% | +53.81 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of ABBV...
Key Statistics
Market Cap
464.88B
P/E Ratio
74.10
Div Yield
2.61%
52W High
$269.39
52W Low
$190.75
Analyst Consensus
ConsensusBuy
Bullish2480.0%
Neutral516.7%
Bearish13.3%
52W Analyst Price Targets
Min Target
$200.00
$200.00
Max Target
$328.00
$328.00
Current$263.21
Avg Target$278.61
Analyst Recommendations
Target Price:$278.61($200.00 - $328.00)
Community Thoughts
Share your analysis and sentiment on ABBV
Join the community to share your analysis
Latest News for ABBV

ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
24/7 Wall St.•Sep 25, 2026, 03:01 PM

ADARx Pharmaceuticals raises $446 million in upsized IPO
Quartz•Sep 25, 2026, 02:06 PM

The Peptide Boom That Isn’t About Your Muscles
The Wall Street Journal•Sep 25, 2026, 09:30 AM
ADARx Pharmaceuticals Prices Upsized $446.3 Million Initial Public Offering
MT Newswires•Sep 25, 2026, 08:27 AM
RNAi drug specialist ADARx raises $446M IPO
BioPharma Dive•Sep 25, 2026, 12:36 AM


AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
Motley Fool•Sep 24, 2026, 09:19 PM

AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
Motley Fool•Sep 24, 2026, 08:22 PM
AbbVie Stays Flat as 6,000-Property AI Hunts Better Molecules
GuruFocus.com•Sep 24, 2026, 07:39 PM

Can Eli Lilly Stock Catch Up To Rivals It Outgrows?
Trefis•Sep 24, 2026, 07:03 PM